Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Fatal neutropenic enterocolitis associated with docetaxel use: A review of cases reported to the United States Food and Drug Administration Adverse Event Reporting System.

Singh P, Nayernama A, Christopher Jones S, Amiri Kordestani L, Fedenko K, Prowell T, Bersoff-Matcha SJ.

J Oncol Pharm Pract. 2019 Oct 8:1078155219879494. doi: 10.1177/1078155219879494. [Epub ahead of print]

PMID:
31594460
2.

Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.

Howie LJ, Singh H, Bloomquist E, Wedam S, Amiri-Kordestani L, Tang S, Sridhara R, Sanchez J, Prowell TM, Kluetz PG, King-Kallimanis BL, Gao JJ, Ibrahim A, Goldberg KB, Theoret M, Pazdur R, Beaver JA.

J Clin Oncol. 2019 Sep 27:JCO1802217. doi: 10.1200/JCO.18.02217. [Epub ahead of print]

PMID:
31560580
3.

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J.

Circulation. 2019 Jul 2;140(2):80-91.

PMID:
31390169
4.

Assessing cardiac safety in oncology drug development.

Seltzer JH, Gintant G, Amiri-Kordestani L, Singer J, Koplowitz LP, Moslehi JJ, Barac A, Yu AF.

Am Heart J. 2019 Aug;214:125-133. doi: 10.1016/j.ahj.2019.04.010. Epub 2019 May 4. Review. No abstract available.

5.

Patient-Friendly Language to Facilitate Treatment Choice for Patients with Cancer.

Kim J, Gao J, Amiri-Kordestani L, Beaver JA, Kluetz P.

Oncologist. 2019 Aug;24(8):1011-1012. doi: 10.1634/theoncologist.2018-0761. Epub 2019 May 16. No abstract available.

6.

Current Landscape of Immunotherapy in Breast Cancer: A Review.

Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA.

JAMA Oncol. 2019 Apr 11. doi: 10.1001/jamaoncol.2018.7147. [Epub ahead of print]

PMID:
30973611
7.

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.

Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, Cohen P, Groarke JD, Herrmann J, Reilly CM, Weintraub NL.

Circulation. 2019 Mar 26;139(13):e579-e602. doi: 10.1161/CIR.0000000000000641. Erratum in: Circulation. 2019 Apr 9;139(15):e838-e839.

8.

FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer.

Howie LJ, Scher NS, Amiri-Kordestani L, Zhang L, King-Kallimanis BL, Choudhry Y, Schroeder J, Goldberg KB, Kluetz PG, Ibrahim A, Sridhara R, Blumenthal GM, Pazdur R, Beaver JA.

Clin Cancer Res. 2019 May 15;25(10):2949-2955. doi: 10.1158/1078-0432.CCR-18-3003. Epub 2018 Dec 14.

PMID:
30552112
9.

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.

Seidman AD, Bordeleau L, Fehrenbacher L, Barlow WE, Perlmutter J, Rubinstein L, Wedam SB, Hershman DL, Hayes JF, Butler LP, Smith ML, Regan MM, Beaver JA, Amiri-Kordestani L, Rastogi P, Zujewski JA, Korde LA.

J Clin Oncol. 2018 Sep 13:JCO1800242. doi: 10.1200/JCO.18.00242. [Epub ahead of print]

PMID:
30212295
10.

Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.

Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steingart RM, Gregory W, Hariharan S, Hammad TA, Lindenfeld J, Murphy MJ, Moslehi JJ; Checkpoint Inhibitor Safety Working Group.

Oncologist. 2018 Aug;23(8):874-878. doi: 10.1634/theoncologist.2018-0157. Epub 2018 May 25.

11.

FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.

Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, Pierre V, Charlab R, Ramamoorthy A, Song P, Li F, Yu J, Manheng W, Palmby TR, Ghosh S, Horne HN, Lee EY, Philip R, Dave K, Chen XH, Kelly SL, Janoria KG, Banerjee A, Eradiri O, Dinin J, Goldberg KB, Pierce WF, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA, Pazdur R.

Clin Cancer Res. 2018 Sep 1;24(17):4066-4071. doi: 10.1158/1078-0432.CCR-18-0042. Epub 2018 Apr 12.

12.

U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer.

Singh H, Walker AJ, Amiri-Kordestani L, Cheng J, Tang S, Balcazar P, Barnett-Ringgold K, Palmby TR, Cao X, Zheng N, Liu Q, Yu J, Pierce WF, Daniels SR, Sridhara R, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA, Pazdur R.

Clin Cancer Res. 2018 Aug 1;24(15):3486-3491. doi: 10.1158/1078-0432.CCR-17-3628. Epub 2018 Mar 9.

13.

US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.

Wedam SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, Tang S, Goldberg KB, Sridhara R, Ibrahim A, Kim G, Kluetz P, McKee A, Pazdur R.

J Clin Oncol. 2018 Apr 20;36(12):1225-1231. doi: 10.1200/JCO.2017.74.6917. Epub 2018 Mar 9.

14.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group.

Lin NU, Prowell T, Tan AR, Kozak M, Rosen O, Amiri-Kordestani L, White J, Sul J, Perkins L, Beal K, Gaynor R, Kim ES.

J Clin Oncol. 2017 Nov 20;35(33):3760-3773. doi: 10.1200/JCO.2017.74.0761. Epub 2017 Oct 2.

PMID:
28968165
15.

21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.

Sheng CC, Amiri-Kordestani L, Palmby T, Force T, Hong CC, Wu JC, Croce K, Kim G, Moslehi J.

JACC Basic Transl Sci. 2016 Aug;1(5):386-398. doi: 10.1016/j.jacbts.2016.05.008.

16.

ANG1005 for breast cancer brain metastases: correlation between 18F-FLT-PET after first cycle and MRI in response assessment.

O'Sullivan CC, Lindenberg M, Bryla C, Patronas N, Peer CJ, Amiri-Kordestani L, Davarpanah N, Gonzalez EM, Burotto M, Choyke P, Steinberg SM, Liewehr DJ, Figg WD, Fojo T, Balasubramaniam S, Bates SE.

Breast Cancer Res Treat. 2016 Nov;160(1):51-59. Epub 2016 Sep 12.

17.

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.

Walker AJ, Wedam S, Amiri-Kordestani L, Bloomquist E, Tang S, Sridhara R, Chen W, Palmby TR, Fourie Zirkelbach J, Fu W, Liu Q, Tilley A, Kim G, Kluetz PG, McKee AE, Pazdur R.

Clin Cancer Res. 2016 Oct 15;22(20):4968-4972. Epub 2016 Jul 12.

18.

The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.

Dine JL, O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S.

Breast Cancer Res Treat. 2016 Jan;155(2):235-51. doi: 10.1007/s10549-015-3673-z. Epub 2016 Jan 12.

19.

Neoadjuvant Therapy As a Platform for Drug Development: Current Controversies and Regulatory Perspectives.

Amiri-Kordestani L, Beaver JA, Cortazar P.

Oncology (Williston Park). 2015 Nov;29(11):843-4, 846. No abstract available.

20.

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.

Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, Zirkelbach JF, Yu J, Liu Q, Zhao L, Crich J, Chen XH, Hughes M, Bloomquist E, Tang S, Sridhara R, Kluetz PG, Kim G, Ibrahim A, Pazdur R, Cortazar P.

Clin Cancer Res. 2015 Nov 1;21(21):4760-6. doi: 10.1158/1078-0432.CCR-15-1185. Epub 2015 Aug 31. Review.

21.

First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.

Amiri-Kordestani L, Wedam S, Zhang L, Tang S, Tilley A, Ibrahim A, Justice R, Pazdur R, Cortazar P.

Clin Cancer Res. 2014 Nov 1;20(21):5359-64. doi: 10.1158/1078-0432.CCR-14-1268. Epub 2014 Sep 9. Review.

22.

FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.

Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, Weinberg WC, Chi B, Candau-Chacon R, Hughes P, Russell AM, Miksinski SP, Chen XH, McGuinn WD, Palmby T, Schrieber SJ, Liu Q, Wang J, Song P, Mehrotra N, Skarupa L, Clouse K, Al-Hakim A, Sridhara R, Ibrahim A, Justice R, Pazdur R, Cortazar P.

Clin Cancer Res. 2014 Sep 1;20(17):4436-41. doi: 10.1158/1078-0432.CCR-14-0012. Epub 2014 May 30.

23.

Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.

Wang J, Song P, Schrieber S, Liu Q, Xu Q, Blumenthal G, Amiri Kordestani L, Cortazar P, Ibrahim A, Justice R, Wang Y, Tang S, Booth B, Mehrotra N, Rahman A.

Clin Pharmacol Ther. 2014 May;95(5):558-64. doi: 10.1038/clpt.2014.24. Epub 2014 Jan 31.

PMID:
24488143
24.

CNS metastases in breast cancer: old challenge, new frontiers.

Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS.

Clin Cancer Res. 2013 Dec 1;19(23):6404-18. doi: 10.1158/1078-0432.CCR-13-0790. Review.

25.

Inflammatory breast cancer: yet another risk of the obesity epidemic?

Amiri-Kordestani L, Kamangar F, Zujewski JA.

J Natl Cancer Inst. 2013 Sep 18;105(18):1340-2. doi: 10.1093/jnci/djt236. No abstract available.

PMID:
24046389
26.

Phase I trial of a new schedule of romidepsin in patients with advanced cancers.

Amiri-Kordestani L, Luchenko V, Peer CJ, Ghafourian K, Reynolds J, Draper D, Frye R, Woo S, Venzon D, Wright J, Skarulis M, Figg WD, Fojo T, Bates SE, Piekarz RL.

Clin Cancer Res. 2013 Aug 15;19(16):4499-507. doi: 10.1158/1078-0432.CCR-13-0095. Epub 2013 Jun 11.

27.

Why do phase III clinical trials in oncology fail so often?

Amiri-Kordestani L, Fojo T.

J Natl Cancer Inst. 2012 Apr 18;104(8):568-9. doi: 10.1093/jnci/djs180. Epub 2012 Apr 6. No abstract available. Erratum in: J Natl Cancer Inst. 2012 Jun 6;104(11):885.

PMID:
22491346
28.

Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.

Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE.

Drug Resist Updat. 2012 Feb-Apr;15(1-2):50-61. doi: 10.1016/j.drup.2012.02.002. Epub 2012 Mar 29. Review.

29.

Pazopanib for the treatment of breast cancer.

Amiri-Kordestani L, Tan AR, Swain SM.

Expert Opin Investig Drugs. 2012 Feb;21(2):217-25. doi: 10.1517/13543784.2012.652304. Epub 2012 Jan 10. Review.

PMID:
22233389
30.

Drug development: portals of discovery.

Bates SE, Amiri-Kordestani L, Giaccone G.

Clin Cancer Res. 2012 Jan 1;18(1):23-32. doi: 10.1158/1078-0432.CCR-11-1001.

31.

Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.

Fojo T, Amiri-Kordestani L, Bates SE.

J Natl Cancer Inst. 2011 Dec 7;103(23):1738-40. doi: 10.1093/jnci/djr386. Epub 2011 Nov 1. Review.

32.

ABC transporters: unvalidated therapeutic targets in cancer and the CNS.

Robey RW, Massey PR, Amiri-Kordestani L, Bates SE.

Anticancer Agents Med Chem. 2010 Oct 1;10(8):625-33. Review.

33.

Follicular dendritic cell sarcoma of the neck: case report and review of current diagnostic and management strategies.

Amiri-Kordestani L, Priebat D, Chia SH.

Ear Nose Throat J. 2010 Jul;89(7):E14-7.

PMID:
20628972
34.

Novel SIL1 mutations in consanguineous Pakistani families mapping to chromosomes 5q31.

Riazuddin SA, Amiri-Kordestani L, Kaul H, Butt T, Jiao X, Riazuddin S, Hejtmancik JF.

Mol Vis. 2009 May 22;15:1050-6.

Supplemental Content

Loading ...
Support Center